Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.

Slides:

Advertisements

Similar presentations

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Advertisements

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Tfr cells’ transcriptomic profile distinguishes them from Treg and Tfh cells. Tfr cells’ transcriptomic profile distinguishes them from Treg and Tfh cells.

Fig. 5 Local gel scaffold for T cell memory response.

Deficiency of TLR9 promotes more severe renal inflammation in imiquimod-induced autoimmunity. Deficiency of TLR9 promotes more severe renal inflammation.

Fig. 4. Dabrafenib and trametinib changed the cellular components of the tumor microenvironment. Dabrafenib and trametinib changed the cellular components.

Fig. 5 Early and modest immune response at day 3 after exposure in Delayed animals. Early and modest immune response at day 3 after exposure in Delayed.

Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.

Fig. 7 Correlation of NHP and human ISGs.

Fig. 5 Correlation of RNA expression and protein abundance.

Fig. 5 Hypoxic tumors from obese mice associate with increased production of IL-6 by adipocytes and myeloid cells. Hypoxic tumors from obese mice associate.

Consolidated Standards of Reporting Trials flow diagram of VRC trial

Fig. 1. Loss of circadian rhythms in iKO mice.

Fig. 2 AcPGP induces IL-8 and G-CSF release from human bronchial epithelial cells. AcPGP induces IL-8 and G-CSF release from human bronchial epithelial.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 1. MSCs undergo in vivo apoptosis after infusion without affecting immunosuppression. MSCs undergo in vivo apoptosis after infusion without affecting.

Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Fig. 5 A competent Fc is required for the antitumor immune response.

Fig. 1. Iontophoretic devices used for the delivery of cytotoxic agents to solid tumors. Iontophoretic devices used for the delivery of cytotoxic agents.

In vivo release of doxycycline hyclate from the GRS in a swine model

Fig. 1 AVPR1A is regulated by the AR coactivator VAV3 and AR-V7 and is increased in advanced human PC. AVPR1A is regulated by the AR coactivator VAV3 and.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Fig. 5. In vivo characterization of adipogenesis by CT.

Gene expression changes associated with response to combination CPI-444 and anti–PD-L1 treatment in MC38 tumors. Gene expression changes associated with.

Fig. 2. Bacterial/viral score in COCONUT-conormalized whole-blood validation data sets. Bacterial/viral score in COCONUT-conormalized whole-blood validation.

Colonization in tumor models and different modes of administration

CD25 expression identifies two transcriptionally distinct subsets of very early effector cells. CD25 expression identifies two transcriptionally distinct.

Fig. 5. Vitamin B12 supplementation in the host altered the transcriptome of P. acnes in the skin microbiota. Vitamin B12 supplementation in the host altered.

Fig. 3. Increased expression of exhaustion markers and apoptosis markers on CAR8 cells in the presence of TCR antigen. Increased expression of exhaustion.

Fig. 1. CAR4 and CAR8 cells demonstrate in vitro and in vivo antileukemic efficacy. CAR4 and CAR8 cells demonstrate in vitro and in vivo antileukemic efficacy.

Fig. 1 Inbred mouse strains carrying monoclonal tumors display a symmetrical yet disparate response to ICB, associated with a distinctive gene signature.

Fig. 4 Administration of BMS to mice inhibits autoimmune-relevant pharmacodynamic endpoints driven by IL-12 and IFNα. Administration of BMS

Fig. 4 Rational therapeutic modulation of the tumor microenvironment sensitizes tumors to ICB. Rational therapeutic modulation of the tumor microenvironment.

Fig. 7 BMS reduces the elevated expression of type I IFN–regulated genes both ex vivo in blood from patients with lupus and in a phase 1 study of.

BMS blocks functional responses in primary immune cells driven by IFNα

Fig. 1. Detection of circulating tumor DNA in CRPC patients.

Fig. 5 Treatment with BMS (PO BID) protects from wasting and colitis in two SCID mouse models. Treatment with BMS (PO BID) protects from.

The microchip-based drug delivery device and overview of study design

Fig. 6. Prolonged miR overexpression in the adult heart reduces fibrotic scar size but compromises cardiac function after MI. Prolonged miR

Fig. 2 Extended local release of agonists of innate immunity prevents tumor recurrence and eliminates distal metastases. Extended local release of agonists.

Fig. 3 Transcriptional changes in dKO mice.

Fig. 2 PK dosing results. PK dosing results. (A) Plasma concentration of hPTH(1–34) versus time after release of 40-μg dose from implanted microchip device.

DAC treatment activates expression of immunoregulatory genes.

Fig. 3 Local Maraba treatment of TNBC tumors provides long-term systemic protection. Local Maraba treatment of TNBC tumors provides long-term systemic.

Fig. 4. Paclitaxel promotes the expression of invasive isoforms of MENA in the primary breast cancer microenvironment. Paclitaxel promotes the expression.

Fig. 1. The HCN channel blocker ivabradine (IVA) is analgesic in a mouse model of type 1 diabetes. The HCN channel blocker ivabradine (IVA) is analgesic.

PD and efficacy of AZD4785 in KRAS mutant lung cancer xenograft models

Fig. 8. Purkinje cell quantification and hearing threshold in NPC cats administered IC HPβCD. Purkinje cell quantification and hearing threshold in NPC.

Fig. 3. Human liver tissue seed graft function.

Tissue architecture affects function of expanded liver seed grafts

Fig. 2. Overexpression of miR cluster in the developing heart results in increased cardiomyocyte proliferation and cardiomegaly. Overexpression.

Fig. 2 Neonatal ZIKV infection induces seizures in young mice and increases susceptibility to chemically induced seizures in adult mice. Neonatal ZIKV.

Fig. 1. GDF15 is up-regulated with obesity, and AAV-GDF15 improves metabolic parameters in DIO mice. GDF15 is up-regulated with obesity, and AAV-GDF15.

miR can promote cardiomyocyte proliferation in the adult heart

Fig. 3. miR overexpression leads to increased cell proliferation as well as altered differentiation and metabolism in cardiomyocytes. miR

Fig. 5 Clustering of the distal gut microbiome, the C

Fig. 3. Association between peak CTL019 expansion and response.

Fig. 1. APP/PS1;C3 KO mice show improved cognitive flexibility (reversal) compared to APP/PS1 mice at 16 months of age. APP/PS1;C3 KO mice show improved.

Fig. 1 Differentiation of human peripheral blood monocytes into MDMi cells induces a microglial gene expression and functional phenotype. Differentiation.

Fig. 6 TNF-α neutralization prevents ZIKV-induced seizures in mice.

Fig. 1. Schematic description of whole-exome or targeted next-generation sequencing analyses. Schematic description of whole-exome or targeted next-generation.

Fig. 6 Pharmacologic alterations of β-AR signaling regulate cardiomyocyte abscission and endowment. Pharmacologic alterations of β-AR signaling regulate.

Fig. 8 Immune correlates of protection.

Fig. 3 Postnatal assembly of the humanized gut microbiota.

Fig. 2. In vivo local CD25-targeted NIR-PIT induces regression of treated LL/2-luc tumors. In vivo local CD25-targeted NIR-PIT induces regression of treated.

Fig. 2 Astrocyte-specific AAV2/5 RiboTag.

Fig. 2. Ex vivo and in vivo investigation of the mechanism of drug delivery enhancement with ultrasound. Ex vivo and in vivo investigation of the mechanism.

Presentation transcript:

Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. On day 5 after ACT, tumors were isolated and snap-frozen immediately (two to three mice in each group). RNA isolation was done after all samples were collected. (A) PCA of gene expression profile of the tested samples. (B) Clustering of immune-related genes with analysis of variance (ANOVA) filter, P < 0.05. Gene names in individual clusters are listed in tables S1 to S3. (C) Clustering of chemokines and their receptors. (D) Clustering of MDAs and MHC class I and II molecules. Siwen Hu-Lieskovan et al., Sci Transl Med 2015;7:279ra41 Copyright © 2015, American Association for the Advancement of Science